Skip to main content

Table 3 Comparisons of the frequencies of inappropriate prescriptions of dabigatran between ambulant patients and inpatients

From: Impact of Pharmacists’ audit on improving the quality of prescription of dabigatran etexilate methanesulfonate: a retrospective study

Checklist of appropriate prescriptions Ambulant patients (n = 131) Inpatients (n = 97) P value
Overall (%) 43 (33) 11 (11) <0.001
Unauthorized indication 0 0 NA
Violation of contraindications
 eGFR < 30 mL/min/1.73 m2 0 [0] 0 [0] NA
 CLCr < 30 mL/min 2 [50] 0 [80] 0.15
 Concomitant use with oral itraconazole 0 0 NA
 Active bleeding or hemorrhagic diathesis 0 0 NA
 History of complications associated with high-risk of bleeding (cerebral hemorrhage) in the latest 6 months 0 0 NA
 Concomitant dwelling of spinal or epidural catheters 0 0 NA
 History of serious hypersensitivity reaction to Prazaxa® 0 0 NA
Inappropriate dose selection in reference to age
 Overdose for patients ≥ 70 years (%) 14/77 (18) 2/56 (4) <0.05
 Underdose for patients ≥ 70 years (%) 2/77 (3) 1/56 (2) NS
 Overdose for patients < 70 years (%) 0/54 (0) 0/41 (0) NA
 Underdose for patients  < 70 years (%) 3/54 (6) 0/41 (0) NS
Non-compliance with the recommendations for dose reduction
 eGFR from 30 to 50 mL/min/1.73 m2 (%) 2/22 (9) 1/10 (10) NS
 CLcr from 30 to 50 mL/min 0/11 (0) 1/15 (7) NS
 Past medical history of gastrointestinal bleeding (%) 1/5 (20) 3/5 (60) NS
 Concomitant use of verapamil (%) 7/10 (70) 3/7 (43) NS
No assessment of renal function (%) 1/131 (1) 0/97 (0) NS
PT-INR < 2.0 when dabigatran was started after discontinuation of warfarin 14/54 (26) 1/21 (5) 0.053
  1. The figures in brackets are numbers of eligible patients
  2. Four cases (3 ambulant patients and 1 inpatient, respectively) had more than one violations of the instructions given in the prescribing information. Statistical analyses were performed with Fisher’s exact test
  3. NA not applicable, NS not significant